- Home
- AMLX vs BME Comparison
AMLX vs BME Comparison
Compare AMLX & BME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMLX
- BME
- Stock Information
- Founded
- AMLX 2014
- BME 2005
- Country
- AMLX United States
- BME United States
- Employees
- AMLX N/A
- BME N/A
- Industry
- AMLX Biotechnology: Pharmaceutical Preparations
- BME Trusts Except Educational Religious and Charitable
- Sector
- AMLX Health Care
- BME Finance
- Exchange
- AMLX Nasdaq
- BME Nasdaq
- Market Cap
- AMLX 481.9M
- BME 525.3M
- IPO Year
- AMLX 2022
- BME N/A
- Fundamental
- Price
- AMLX $3.45
- BME $39.90
- Analyst Decision
- AMLX Buy
- BME
- Analyst Count
- AMLX 7
- BME 0
- Target Price
- AMLX $7.60
- BME N/A
- AVG Volume (30 Days)
- AMLX 921.2K
- BME 34.0K
- Earning Date
- AMLX 02-20-2025
- BME 01-01-0001
- Dividend Yield
- AMLX N/A
- BME 6.26%
- EPS Growth
- AMLX N/A
- BME N/A
- EPS
- AMLX N/A
- BME 1.44
- Revenue
- AMLX $196,485,000.00
- BME N/A
- Revenue This Year
- AMLX N/A
- BME N/A
- Revenue Next Year
- AMLX N/A
- BME N/A
- P/E Ratio
- AMLX N/A
- BME $28.37
- Revenue Growth
- AMLX N/A
- BME N/A
- 52 Week Low
- AMLX $1.58
- BME $35.53
- 52 Week High
- AMLX $19.95
- BME $43.20
- Technical
- Relative Strength Index (RSI)
- AMLX 38.58
- BME 63.15
- Support Level
- AMLX $3.02
- BME $38.63
- Resistance Level
- AMLX $3.67
- BME $39.44
- Average True Range (ATR)
- AMLX 0.26
- BME 0.54
- MACD
- AMLX 0.01
- BME 0.21
- Stochastic Oscillator
- AMLX 37.07
- BME 99.80
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.